lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications

24 Pages Posted: 9 Apr 2020

See all articles by Fan Wu

Fan Wu

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Aojie Wang

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Mei Liu

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Qimin Wang

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Jun Chen

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Shuai Xia

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS); Fudan University - Shanghai Public Health Clinical Center

Yun Ling

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Yuling Zhang

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Jingna Xun

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Lu Lu

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS); Fudan University - Shanghai Public Health Clinical Center

Shibo Jiang

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS); Fudan University - Shanghai Public Health Clinical Center

Hongzhou Lu

Fudan University - Department of Clinical Laboratory; Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

Yumei Wen

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS); Fudan University - Shanghai Public Health Clinical Center

Jinghe Huang

Fudan University - Shanghai Public Health Clinical Center; Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

More...

Abstract

Background: The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients.

Methods: Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time.

Findings: SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus. SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter. The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions. The titers of NAbs were variable in different patients. Elderly and middle-age patients had significantly higher plasma NAb titers (P<0·0001) and spike-binding antibodies (P=0·0003) than young patients. Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively. The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response.

Interpretation: The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression. The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus. Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment.

Funding Statement: This work was supported by the National Major Science and Technology Projects of China (2017ZX10202102 and 2018ZX10301403), National Natural Science Foundation of China (31771008), Hundred Talent Program of Shanghai Municipal Health Commission (2018BR08), and Chinese Academy of Medical Sciences (2019PT350002).

Declaration of Interests: The authors declare no competing interests.

Ethics Approval Statement: The study was conducted under a clinical protocol approved by the Investigational Review Board in the Shanghai Public Health Clinical Center (Study number: YJ-2020-S021-01). All participants signed an informed consent approved by the IRB.

Keywords: COVID-19; SARS-CoV-2; Neutralizing antibody

Suggested Citation

Wu, Fan and Wang, Aojie and Liu, Mei and Wang, Qimin and Chen, Jun and Xia, Shuai and Ling, Yun and Zhang, Yuling and Xun, Jingna and Lu, Lu and Jiang, Shibo and Lu, Hongzhou and Wen, Yumei and Huang, Jinghe, Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications (3/28/2020). Available at SSRN: https://ssrn.com/abstract=3566211 or http://dx.doi.org/10.2139/ssrn.3566211

Fan Wu

Fudan University - Shanghai Public Health Clinical Center ( email )

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) ( email )

138 Dong’an Rd
Shanghai, 200032
China

Aojie Wang

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Mei Liu

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Qimin Wang

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Jun Chen

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Shuai Xia

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Yun Ling

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Yuling Zhang

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Jingna Xun

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Lu Lu

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Shibo Jiang

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS)

138 Dong’an Rd
Shanghai, 200032
China

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Hongzhou Lu

Fudan University - Department of Clinical Laboratory ( email )

2901 Caolang Road
Jinshan District
Shanghai, 201508
China

Fudan University - Shanghai Public Health Clinical Center ( email )

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) ( email )

138 Dong’an Rd
Shanghai, 200032
China

Yumei Wen

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) ( email )

138 Dong’an Rd
Shanghai, 200032
China

Fudan University - Shanghai Public Health Clinical Center

Shanghai
China

Jinghe Huang (Contact Author)

Fudan University - Shanghai Public Health Clinical Center ( email )

Shanghai
China

Fudan University - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) ( email )

138 Dong’an Rd
Shanghai, 200032
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
5,309
Downloads
1,359